These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 36406648)
1. A Phase 3 clinical trial validating the potency and safety of an innovative, extra-long-acting interferon in chronic hepatitis C. Chen CY; Chuang WL; Qin A; Zhang WH; Zhu LY; Zhang GQ; Chen JJ; Lo CC; Zhou X; Mao X; Shang J; Kuo HT; Xie W; Chen CH; Lo GH; Jun DW; Dang S; Tsai CY; Wang TF; Lai HH; Tseng KC; Huang YW; Chen PJ JGH Open; 2022 Nov; 6(11):782-791. PubMed ID: 36406648 [TBL] [Abstract][Full Text] [Related]
2. Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C. Hsu SJ; Yu ML; Su CW; Peng CY; Chien RN; Lin HH; Lo GH; Su WW; Kuo HT; Hsu CW; Yang SS; Yang SS; Tseng KC; Qin A; Huang YW; Chuang WL J Formos Med Assoc; 2021 Mar; 120(3):956-964. PubMed ID: 33077341 [TBL] [Abstract][Full Text] [Related]
3. Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy. Lin HH; Hsu SJ; Lu SN; Chuang WL; Hsu CW; Chien RN; Yang SS; Su WW; Wu JC; Lee TH; Peng CY; Tseng KC; Qin A; Huang YW; Chen PJ JGH Open; 2021 Aug; 5(8):929-940. PubMed ID: 34386602 [TBL] [Abstract][Full Text] [Related]
4. A therapeutic dose and its pharmacokinetics of ropeginterferon Alfa-2b for hepatitis C treatment. Lo CC; Chuang WL; Kuo HT; Chen WM; Qin A; Tsai CY; Huang YW; Chen CY J Formos Med Assoc; 2024 Jan; 123(1):55-61. PubMed ID: 37666718 [TBL] [Abstract][Full Text] [Related]
5. Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B. Huang YW; Hsu CW; Lu SN; Yu ML; Su CW; Su WW; Chien RN; Hsu CS; Hsu SJ; Lai HC; Qin A; Tseng KC; Chen PJ Hepatol Int; 2020 Dec; 14(6):997-1008. PubMed ID: 33099752 [TBL] [Abstract][Full Text] [Related]
6. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Gisslinger H; Klade C; Georgiev P; Krochmalczyk D; Gercheva-Kyuchukova L; Egyed M; Rossiev V; Dulicek P; Illes A; Pylypenko H; Sivcheva L; Mayer J; Yablokova V; Krejcy K; Grohmann-Izay B; Hasselbalch HC; Kralovics R; Kiladjian JJ; Lancet Haematol; 2020 Mar; 7(3):e196-e208. PubMed ID: 32014125 [TBL] [Abstract][Full Text] [Related]
7. Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis. Huang YW; Qin A; Tsai CY; Chen PJ Viruses; 2022 May; 14(6):. PubMed ID: 35746606 [TBL] [Abstract][Full Text] [Related]
8. Novel long-acting ropeginterferon alfa-2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial. Huang YW; Qin A; Fang J; Wang TF; Tsai CW; Lin KC; Teng CL; Larouche R Br J Clin Pharmacol; 2022 May; 88(5):2396-2407. PubMed ID: 34907578 [TBL] [Abstract][Full Text] [Related]
9. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224 [TBL] [Abstract][Full Text] [Related]
10. A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19. Liu WD; Feng PH; Cheng CY; Chou CL; Lee CH; Lu MC; Liu PY; Lee MH; Liao CH; Chen MC; Chen CP; Hsu SF; Tzeng YT; Lin YC; Ou TY; Qin A; Tsai CY; Shih WJ; Lee KY; Sheng WH Infect Dis Ther; 2024 Jul; 13(7):1575-1588. PubMed ID: 38771550 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Pharmacodynamics of Novel Long-Acting Ropeginterferon Alfa-2b in Healthy Chinese Subjects. Huang YW; Tsai CY; Tsai CW; Wang W; Zhang J; Qin A; Teng C; Song B; Wang MX Adv Ther; 2021 Sep; 38(9):4756-4770. PubMed ID: 34328630 [TBL] [Abstract][Full Text] [Related]
12. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options. Kiladjian JJ; Marin FF; Al-Ali HK; Alvarez-Larrán A; Beggiato E; Bieniaszewska M; Breccia M; Buxhofer-Ausch V; Cerna O; Crisan AM; Danaila CD; De Stefano V; Döhner K; Empson V; Gora-Tybor J; Griesshammer M; Grosicki S; Guglielmelli P; García-Gutierrez V; Heidel FH; Illés A; Tomuleasa C; James C; Koschmieder S; Krauth MT; Krejcy K; Lazaroiu MC; Mayer J; Nagy ZG; Nicolini FE; Palandri F; Pappa V; Reiter AJ; Sacha T; Schlager S; Schmidt S; Terpos E; Unger M; Wölfler A; Cirici BX; Klade C Ann Hematol; 2024 Jul; 103(7):2299-2310. PubMed ID: 38438627 [TBL] [Abstract][Full Text] [Related]
13. A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera. Illés Á; Pinczés LI; Egyed M Expert Opin Drug Metab Toxicol; 2021 Jan; 17(1):3-7. PubMed ID: 33118413 [TBL] [Abstract][Full Text] [Related]
14. Study Protocol of a Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in COVID-19 Patients with Comorbidities. Liu WD; Hou HA; Li KJ; Qin A; Tsai CY; Sheng WH Adv Ther; 2024 Feb; 41(2):847-856. PubMed ID: 38010606 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration. Miyachi N; Zagrijtschuk O; Kang L; Yonezu K; Qin A Clin Drug Investig; 2021 Apr; 41(4):391-404. PubMed ID: 33725322 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study. Edahiro Y; Ohishi K; Gotoh A; Takenaka K; Shibayama H; Shimizu T; Usuki K; Shimoda K; Ito M; VanWart SA; Zagrijtschuk O; Qin A; Kawase H; Miyachi N; Sato T; Komatsu N; Kirito K Int J Hematol; 2022 Aug; 116(2):215-227. PubMed ID: 35430707 [TBL] [Abstract][Full Text] [Related]
17. Clinical Experience with Ropeginterferon Alfa-2b in the Off-Label Use for the Treatment of COVID-19 Patients in Taiwan. Chen KY; Lee KY; Qin A; Luo CS; Yeh YK; Zheng JQ; Chen CM; Tsai CY; Lin S; Liao J; Huang YW; Feng PH Adv Ther; 2022 Feb; 39(2):910-922. PubMed ID: 34910280 [TBL] [Abstract][Full Text] [Related]
18. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C; JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915 [TBL] [Abstract][Full Text] [Related]
19. Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera. Qin A; Wu D; Li Y; Zhang J; Wang W; Shen W; Liao J; Lin S; Chang C; Chen H; Cui J; Su X Br J Clin Pharmacol; 2024 Jun; 90(6):1493-1502. PubMed ID: 38500445 [TBL] [Abstract][Full Text] [Related]